Company news
Amplia Therapeutics Ltd. (ASX:ATX) news
Amplia Therapeutics Ltd. news releases on 6ix. Latest, Dec 16, 2021: Amplia Provides Updated Investor Presentation
Press releases — page 3
Amplia Provides Updated Investor Presentation
December 15, 2021
Entitlement Offer Completed
December 10, 2021
Amplia Awarded $2.1M R&D Cash Flow Loan
December 2, 2021
App 4D and Financial Report Half Year ended 30 Sep 2021
November 24, 2021
Inhibition of FAK by AMP945 in Phase 1 Clinical Trial
November 16, 2021
Capital Raising Investor Presentation
November 7, 2021
Entitlement Offer Prospectus
November 7, 2021
Placement and Underwritten Entitlement Offer to Raise $12.4m
November 7, 2021
Quarterly Activities and Cashflow Reports - Sep 2021 Qtr
October 27, 2021
Amplia Receives $1.1m R&D Tax Incentive
October 13, 2021
New Garvan Publication Supports Amplia Phase 2 Design
September 29, 2021
Phase 2 Trial in First-Line Pancreatic Cancer Patients
September 14, 2021
AGM - Chief Executive Officers Presentatioin
August 27, 2021
Quarterly Activities and Cashflow Reports and Presentation
July 27, 2021
Results from Successful Phase 1 Clinical Trial of AMP945
July 20, 2021
Amplia and Garvan Enter Into Collaboration Agreement
June 27, 2021
AMP945 Improves Survival in Pacnreatic Cancer Model
June 1, 2021
App 4E - Preliminary Final Report YE 31 March 2021
May 31, 2021
Proposed issue of Securities - ATX
May 4, 2021
Amplia Announces $3.8m Share Placement
May 3, 2021
Preclinical Data Support Developmnt AMP945 Pancreatic Cancer
April 27, 2021
ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH
April 19, 2021
Amplia Completes Dosing in Phase 1 Clinical Study of AMP945
April 14, 2021
Amplia and Garvan Institute Enter Collaboration Agreement
March 17, 2021
Amplia Completes Single Dose Study of AMP945
March 16, 2021
Amplia Initiates Multiple Dose Study of AMP945
February 16, 2021
Investor Update - February 2021
February 10, 2021
Quarterly Activities and Cashflow Reports - Dec 2020 Qtr
January 27, 2021
Amplia Receives $0.53m R&D Tax Incentive
December 1, 2020
Appendix 4D and Financial Report Half Year Ended 30 Sep 2020
November 27, 2020
ATX - Sep 2020 Quarter Activities and Cashflow Reports
October 28, 2020
Response to ASX Price Query
October 20, 2020
First Human Dose in Phase 1 Clinical Trial of AMP945
October 8, 2020
Amplia Receives Ethics Clearance fo Conduct Phase 1 Trial
September 7, 2020
Quarterly Activities and Cashflow Reports - June 2020
July 26, 2020
Nucleus Network Appointed to Conduct Phase 1 Clinical Trial
July 22, 2020
Institutional Entitlement Offer Completed
July 2, 2020
Capital Raising - Investor Presentation
July 1, 2020
Preliminary Toxicology Studies Support Phase1 Clinical Trial
June 30, 2020
Preliminary Final Report - YE 31 March 2020
May 29, 2020
FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis
May 19, 2020
Quarterly Activities Report - March 2020 Qtr
April 27, 2020
FDA Awards Orphan Drug Designation for Pancreatic Cancer
March 24, 2020
Dr. John Lambert appointed as Managing Director
February 6, 2020
Appendix 4C Cash Flow - Dec 2019 Qtr
January 29, 2020
Amplia Therapeutics Undertakes Placement
January 19, 2020
App 4D - Financial Report Half Year Ended 30 Sep 2019
November 29, 2019
App 4C - Sep 2019 Qtr Cash Flows Statement
October 31, 2019
Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr
July 31, 2019
Amplia Therapeutics Reports Lead Candidate Preclinical Data
July 23, 2019